Clinical Trials

A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

Cancer Type

Solid Tumor

ClinicalTrials.gov Identifier

NCT06792552

Principal Investigator

Daruka Mahadevan, MD, PhD

For more information about this study
View Details

About This Study

Part 1 (dose escalation): to evaluate the safety and tolerability of SIM0505 and determine the maximum tolerated dose (MTD)